



Alkalon launches new nicotine gum portfolio in Europe

Alkalon's new nicotine gums were granted Marketing Approval in several European countries earlier this year and the company is now launching a portfolio of products.

COPENHAGEN, November 30, 2012. Alkalon today announced that the authorities have granted Alkalon's new nicotine gum portfolio marketing approval in a number of European countries. The new product portfolio includes 2 and 4 mg nicotine in different flavours with coating and will be marketed by a number of generic companies. Alkalon is currently the only company which offers licensing and the supply of high quality nicotine gums to the generics industry in Europe.

"We are pleased that our products finally reached the market" said Bo Tandrup, Alkalon's Chief Executive Officer. "Alkalon has now matured from a development company to an operating business. This is a major achievement for us and we are excited about entering this next phase in our development of Alkalon. We still have a strong focus on the development of new applications and we look forward to maturing these projects as well."

Alkalon has spent 3 years to develop and register the new nicotine gum portfolio. The products are indicated for the treatment of tobacco dependence by relieving nicotine withdrawal symptoms including cravings, thereby facilitating smoking cessation or temporary smoking reduction in smokers motivated to quit smoking.

About Alkalon's nicotine gum

"We have worked hard to create products of superior quality" said Formulation Scientist and Project Manager, Lene Jorsal. "What we have achieved is a pleasant soft gum with a very crunchy coating and two revolutionary flavours: A fresh mint with a dash of lemon and a tasty lemon flavour with notes of mint and mango".

About Alkalon

Alkalon is an independent, privately-owned contract research and product development company based in Denmark. The company specialises in the development of medicated chewing gum formulations and is working in partnership with pharmaceutical companies on dosage form development projects and the supply of finished products.